Related Experiment Video
Updated: Jun 24, 2026

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
Published on: May 13, 2021
Herpes simplex virus oncolytic therapy for pediatric malignancies
Gregory K Friedman1, Joseph G Pressey, Alyssa T Reddy
1Department of Pediatrics, Children's Hospital of Alabama, University of Alabama at Birmingham, USA. gfriedman@peds.uab.edu
Abstract:
Despite improving survival rates for children with cancer, a subset of patients exist with disease resistant to traditional therapies such as surgery, chemotherapy, and radiation. These patients require newer, targeted treatments used alone or in combination with more traditional approaches. Oncolytic herpes simplex virus (HSV) is one of these newer therapies that offer promise for several difficult to treat pediatric malignancies. The potential benefit of HSV therapy in pediatric solid tumors including brain tumors, neuroblastomas, and sarcomas is reviewed along with the many challenges that need to be addressed prior to moving oncolytic HSV therapy from the laboratory to the beside in the pediatric population.
Insights
Oncolytic herpes simplex virus (HSV) offers a promising new treatment for pediatric cancers resistant to traditional therapies. Further research is needed to overcome challenges before clinical application in children.
Area of Science:
- Oncology
- Virology
- Pediatric Medicine
Background:
- Pediatric cancer survival rates are improving, yet some children develop treatment-resistant disease.
- Traditional therapies like surgery, chemotherapy, and radiation are ineffective for a subset of pediatric cancers.
- Novel therapeutic strategies are essential for managing difficult-to-treat pediatric malignancies.
Purpose of the Study:
- To review the potential benefits of oncolytic herpes simplex virus (HSV) therapy for pediatric solid tumors.
- To discuss the application of HSV therapy in challenging pediatric cancers such as brain tumors, neuroblastomas, and sarcomas.
- To identify the challenges hindering the translation of oncolytic HSV therapy from laboratory research to clinical practice in pediatric patients.
Main Methods:
- Literature review of oncolytic herpes simplex virus (HSV) therapy.
- Analysis of existing research on HSV in pediatric oncology.
- Identification of challenges in clinical translation for pediatric populations.
Main Results:
- Oncolytic herpes simplex virus (HSV) demonstrates promise as a targeted therapy for pediatric cancers.
- Potential applications include brain tumors, neuroblastomas, and sarcomas.
- Significant challenges remain in advancing HSV therapy for pediatric use.
Conclusions:
- Oncolytic HSV therapy represents a potential advancement for pediatric malignancies unresponsive to conventional treatments.
- Addressing challenges is crucial for successful clinical implementation in pediatric patients.
- Further research and development are required to realize the full potential of HSV-based cancer therapies in children.
Related Concept Videos
Herpes
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Genital Herpes

